# Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

> **NCT02635789** · PHASE3 · COMPLETED · sponsor: **Nobelpharma** · enrollment: 62 (actual)

## Conditions studied

- Tuberous Sclerosis
- Angiofibroma
- Hypomelanotic Macule
- Plaque

## Interventions

- **DRUG:** NPC-12G gel
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT02635789
- **Lead sponsor:** Nobelpharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02635789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02635789, "Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02635789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*